Anyone who still thinks that AstraZeneca paid too much when it offered a hefty premium for MedImmune's shares should check out a new report from Jefferies International, which estimates that the global swine flu windfall will be worth around $2.3 billion in new sales for the Maryland manufacturer in 2009 and 2010. Report